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Abstract 
Despite a plethora of medical advancements, malignant tumors remain difficult to treat 
due to complex cancer biology and interpatient heterogeneity. Phenotypically similar tumors 
may respond differently to a given treatment. In clinical oncology, it is paramount to quantify 
tumor response to therapy for predicting treatment outcome, monitoring tumor changes, 
identifying effective therapies, and avoiding unnecessary cost and toxicity to the patient. Current 
standards of monitoring tumor response to therapy include CT, MRI, PET, and histopathology; 
these methods either take a merely anatomical approach or are invasive and time consuming, 
necessitating a functional biomarker approach. MPM represents a metabolic-level method of 
effectively quantifying tumor response that is noninvasive and achieves high spatial resolution 
and increased imaging depth. This thesis pursued creation of a benchmark for 5-FU-induced 
apoptosis in CRC cells based on CC3 frequency in order to use this marker to verify TPEFM as 
an ex vivo method of quantifying patient-specific CRC tumor response to 5-FU via changes in 
optical redox ratio as an indicator of apoptosis. Lack of sensitivity of the Western blot protocol 
to CC3 precluded accurate quantification of CC3 frequency over 5-FU exposure times and 
concentrations. Significant changes in redox ratio throughout 5-FU exposure times were 
observed but may remain inconclusive when considering the metabolic properties of most 
cancers. Although redox ratio imaging was successfully conducted here, redox ratio data was not 
correlated with a reliable marker of apoptosis in the same context. With further apoptosis assays 
and more rigorous exploration of the relationship of redox ratio, the metabolic profile of CRC 
cells, and 5-FU-induced apoptosis in CRC cells, TPEFM may be established as a high-resolution 
metabolic technique for monitoring treatment effectiveness in this context and with novel drugs 
and other cancer types. 
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Introduction 
 Problem Overview and Current Approaches 
Approximately 38% of men and women will be diagnosed with cancer at some point in 
their life, and the U.S. national expenditure for care totaled $147 billion in 2017. (1) Furthermore, 
cancerous tumors with apparently similar phenotypes may not respond identically to a given 
treatment, a testament to current limits in the understanding of the complexity of tumor biology 
and how this biology determines tumor response to a given therapy. (1) It remains that measuring 
tumor response to therapy is vital in clinical oncology for predicting treatment outcome, 
monitoring tumor changes, identifying effective therapies, and avoiding unnecessary cost and 
toxicity. (2) Thus, it becomes necessary to monitor cancer treatment efficacy at an individual level 
due to complex tumor biology and interpatient heterogeneity. 
Current standards for quantifying tumor response to therapy include measuring tumor 
shrinkage through imaging (CT, MRI, PET), a method that suffers from interobserver variability, 
difficult differentiation of non-viable tumor and fibrotic tissue from malignant tumor, and 
inadequate spatial resolution to quantify changes at the subcellular level. (3) Furthermore, tumor 
shrinkage may not always be indicative of treatment effectiveness. This issue also arises in drug 
testing: tumor response to therapy is a useful surrogate for clinical benefit of new drugs, but current 
tumor shrinkage criteria may not be beneficial for assessing the efficacy of drugs with novel 
mechanisms of action. (1) Additional histopathological methods involve invasive needle biopsies 
that suffer from sampling error and time-consumption. (2-4) Lastly, serum markers for treatment 
effectiveness tend to be present in low concentrations and thus may be misleading. (1) The ultimate 
indicator of treatment effectiveness is improvement in symptoms and survival; however, earlier 
and more objective/quantifiable metrics are necessary. Tumor response measurements should shift 
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from an anatomical approach to a functional-biomarker approach to achieve more objective 
information at the subcellular level and increase treatment efficiency by balancing treatment cost 
and efficacy through halting ineffective treatments and moving on to effective treatments faster. 
(3) 
Colorectal Cancer, 5-FU Chemotherapy, and Apoptosis 
Colorectal cancer (CRC) specifically is responsible for the third most cancer-related deaths 
in the U.S. and is the fourth most common cancer. (5, 6) Especially since it is generally considered 
incurable after metastasis, CRC is an example of a very common tumorigenic disease that could 
benefit from more effective methods of monitoring tumor response to therapy. (7) The current first 
line of treatment for CRC tumors is the chemotherapeutic drug 5-fluorouracil (5-FU), which serves 
to induce apoptosis in CRC cells. (8, 9) The 5-FU mechanism of action involves a metabolite of 
5-FU complexing with thymidylate synthetase, preventing DNA synthesis. (9) The lack of DNA 
synthesis and repair is a key initiator of apoptosis through the intrinsic pathway, as the 
accumulation of DNA genotoxins results in the development of critical lesions, such as DNA 
double-stranded breaks, followed by caspase activation. (10, 11) Caspases are often used as 
markers of apoptosis due to their direct role in the apoptosis pathway. (2) Activation of effector 
caspases, such as caspase-3 (cleaved caspase-3 (CC3) in the activated form), is considered a 
reliable marker of apoptosis because the apoptosis pathway converges at effector caspases to 
proceed irreversibly to cell death via DNA, nuclear protein, and cytoskeletal protein degradation. 
This is followed by chromatin and cytoplasmic condensation, nuclear fragmentation, and, finally, 
formation of apoptotic bodies consisting of the cellular debris. (2) Thus, it remains that detection 
of CC3 in CRC cells that undergo 5-FU-induced apoptosis is a reliable and quantifiable marker of 
apoptosis activity and, consequently, treatment efficacy in the lab. (12) 
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Multiphoton Microscopy and Optical Redox Ratio Imaging 
Multi-photon microscopy (MPM) is a fluorescence microscopy method with two-photon 
excitation that permits superior 3-D image reconstruction with minimum photobleaching and 
background noise. (13) MPM allows imaging of live cellular processes with improved spatial 
resolution and precision at useful sampling depths. (13) Two-photon excitation fluorescence 
microscopy (TPEFM) is a metabolic-level method that can be used to quantify important sub-
cellular autofluorescent metabolic cofactors, namely reduced nicotinamide adenine dinucleotide 
(NADH) and oxidized flavin adenine dinucleotide (FAD). (14) FAD and NADH occupy critical 
roles in facilitating oxidation-reduction reactions in glycolysis, the citric acid cycle, and oxidative 
phosphorylation. (14) Because FAD fluoresces in the oxidized form and NADH fluoresces in the 
reduced form with no exogenous fluorophores, these cofactors may be used to quantify tumor cell 
metabolism and changes thereto due to apoptosis by quantification of an optical oxidation-
reduction ratio (redox ratio), indicative of metabolic activity. (14-16) Optical redox ratio 
essentially reports the ratio of oxidative phosphorylation to glycolysis as a metric of metabolic 
activity and consequent tumor characteristics. (4, 7, 12, 17-20) Thus, MPM is a method of 
effectively quantifying tumor response to disease treatment and novel drugs that is noninvasive, 
live, metabolic-level, and achieves high spatial resolution and increased imaging depth for 
monitoring of functional cellular changes. (4, 6, 7, 12, 21) 
Objectives 
This thesis describes how MPM may be evaluated as a potential clinical means for 
quantifying tumor response by comparison with known markers of treatment success in the same 
context of cell line and chemotherapy. The objective is to create a standard for 5-FU-induced 
apoptosis in colorectal cancer cells by measuring the occurrence of CC3 in treated cells over time, 
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then evaluate MPM against the caspase standard as a potential ex vivo method to quantify patient-
specific tumor response to 5-FU, specifically quantifying redox ratio as a marker for apoptosis 
frequency and thus treatment efficacy. 
Materials and Methods 
 Cell Culture 
HCT116 CRC cells (American Type Culture Collecation, VA, USA) taken from 
cryopreservation were expanded in a T-75 flask using standard cell culture procedures. Cells were 
incubated at 5% CO2 and 37° C. Cells were fed every 48 hours with complete media consisting of 
McCoy’s base media (Thermo Fisher Scientific Inc., Waltham, MA), 10% fetal bovine serum 
(American Type Culture Collecation, VA, USA), 1% penicillin-streptomycin (Sigma-Aldrich, St. 
Louis, MO), and 0.2% gentamicin/amphotericin (Thermo Fisher Scientific Inc., Waltham, MA). 
CC3 Western Blot 
After expansion, cells were plated in 6-well plates at a density of 0.3x106 cells/well. The 
cells were allowed to expand according to standard cell culture procedures to 80% confluence in 
the 6-well plates before being treated with 5-FU. Three control groups and 4 treatment groups were 
used in these experiments. The control groups consisted of 0 μM 5-FU treatment for exposure 
times of 0, 12, and 24 hours. The treatment groups consisted of 10 and 20 μM 5-FU treatment for 
exposure times of 12 and 24 hours. A 16-hour exposure time was also used in place of the 12-hour 
exposure time in some experiments to maintain consistency with timepoints used in other apoptosis 
assays being conducted in the lab. 5-FU doses were administered in solution with media, and the 
media was not changed during the treatment period. Treatment and control groups cells were 
harvested according to their respective exposure times: the cells were washed with dPBS, 
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unadhered with trypsin-EDTA, moved to a 15 mL conical tube, then centrifuged at 500 g for 5 
minutes. Next, the supernatant was removed, and the cells rewashed with dPBS and centrifugation 
twice more before suspension in 1 mL of dPBS in an Eppendorf tube. The Eppendorf tube was 
centrifuged at 10,000 g for 5 minutes. The supernatant was removed, and the cells were 
resuspended in 100 µL of complete RIPA lysis buffer solution, then recentrifuged at 10,000 g for 
5 minutes. The lysate collected was stored in a -80° C freezer until use in a BCA assay to quantify 
total protein content for preparation of Western blot samples. 
Western blotting followed with an optimized CC3 blotting protocol with β-actin serving as 
a loading control (to control for lane variance) and a standard protein sample, or protein ladder, as 
an exposure control (to control for gel variance). 70 µg of protein was loaded for SDS-PAGE; the 
system ran at 200 V for approximately 45 minutes. Next, transfer took place at 4º C on ice for 20 
hours at 10 V. Protein was transferred to a PVDF membrane with 0.2 µm pores. After transfer was 
complete, regions of interest were cut and blocked using a blocking buffer (Li-Cor) for 2 hours at 
room temperature. The regions of interest include CC3 fragments appearing at 17 and 19 kDa and 
β-actin, appearing at approximately 42 kDa. Primary antibody staining occurred at 4º C overnight. 
Secondary antibody staining was performed at room temperature for 1 hour. The membrane was 
then washed several times before imaging on an Odyssey near infrared scanner. Band 
quantification was attempted by densitometric analysis in ImageJ. Identical rectangular regions 
along the same axis were drawn around bands. Finally, band intensities were partitioned from 
background intensities on intensity histograms of the selected regions with little to no success. 
Multiphoton Microscopy of Optical Redox Ratio 
After expansion, cells were plated in 35 mm round, No. 1.5 coverslip MatTek glass-bottom 
dishes (MA, USA) at a density of 0.3x106 cells/well. The cells were allowed to expand to 80% 
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confluence in the glass-bottom dishes before being treated with 5-FU. One control group and 2 
treatment groups were used in these experiments. The control group consisted of 0 μM 5-FU 
treatment for an exposure time of 0 hours. The treatment groups consisted of 10 μM 5-FU treatment 
for exposure times of 16 and 24 hours. 5-FU doses were administered in solution with media, and 
the media was not changed during the treatment period. Cells were plated, expanded, and treated 
according to treatment group exposure times so that all groups could undergo MPM the same day. 
MPM redox ratio imaging was performed using a custom-built TPEFM. (4) Cell dishes were 
placed in a microincubator at standard conditions for the duration of imaging. Each field of view 
was comprised of two images: NADH intensity and FAD intensity. (4) The FAD channel was 
imaged with an excitation wavelength of 760 nm and an emission wavelength of 460 nm; the 
NADH channel was imaged with an excitation wavelength of 850 nm and an emission wavelength 
of 525 nm. Both channels were imaged with 60 mW of power at the sample, 100 gain, and 2X 
magnification for a 200-frame average at 58 frames/sec (256x256 pixel images, resolution=1.25 
μm/pixel). Seven fields of view were imaged for the control group, 7 for the 16-hour treatment 
group, and 6 for the 24-hour treatment group. A custom CellProfiler pipeline (Version 3.1.9) was 
used to segment the cytoplasm of individual cells from nuclei and background and generate a mask 
based on NADH images. The NADH image mask was then applied to the FAD image in the same 
field of view. Redox ratio was then quantified on a per pixel basis using the channel intensity 
formula 
𝐹𝐴𝐷
𝐹𝐴𝐷+𝑁𝐴𝐷𝐻
 and the median redox ratio computed for individual cells. 
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Results 
CC3 Western Blot 
Figure 1: The CC3 Western blot reveals little to no fluorescence at 17 and 19 kDa relative to 
background noise and loading control, precluding accurate quantification of CC3 band intensity. 
 
 
A: CC3 Western blot membrane section. Lanes: (1) protein ladder; (2) 0 hour, 0 µM [5-FU]; (3) 8 
hour, 10 µM [5-FU]; (4) 16 hour, 10 µM [5-FU]; (5) 24 hour 10 µM [5-FU].  800 nm excitation. 
Faint bands at 17 and 19 kDa corresponding to the fragments of CC3 appear slightly more intense 
than background noise. 
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B: Figure 1:A WB membrane section showing the band quantification process. The identical 
regions are shown drawn around each full lane from approximately 15-22 kDa. The plot shows 
changes in relative intensity moving in the Y direction across each region from the bottom of the 
region to the top. Intensity peaks separated by regions of lower intensity correspond to CC3 bands 
at 17 and 19 kDa but appear only slightly more intense than intra-lane background, preventing 
accurate partitioning of the band area from the background area and thus preventing accurate 
identification/quantification of CC3 band intensities. 
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C: CC3 Western blot membrane section. Lanes: (1) protein ladder; (2) 0 hour, 0 µM [5-FU]; (3) 
12 hour, 0 µM [5-FU]; (4) 12 hour, 10 µM [5-FU]; (5) 12 hour, 20 µM [5-FU]; (6) 24 hour, 0 µM 
[5-FU]; (7) 24 hour, 10 µM [5-FU]; (8) 24 hour, 20 µM [5-FU]. 700 nm excitation. The bands at 
approximately 42 kDa correspond to the β-actin loading control and appear clearly, with no bands 
corresponding to CC3 visible. 
 
 
D: Figure 1:C Western blot membrane section. 800 nm excitation. The blurry bands around 17 
and 19 kDa corresponding to CC3 appear slightly more intense than background noise. 
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E: CC3 Western blot membrane section. Lanes: (1) protein ladder; (2) 0 hour, 0 µM [5-FU]; (3) 
12 hour, 0 µM [5-FU]; (4) 12 hour, 10 µM [5-FU]; (5) 12 hour, 20 µM [5-FU]; (6) 24 hour, 0 µM 
[5-FU]; (7) 24 hour, 10 µM [5-FU]; (8) 24 hour, 20 µM [5-FU]. 700 nm excitation. The bands at 
42 kDa corresponding to β-actin loading control appear relatively more intense than background 
noise, with no bands corresponding to CC3 visible. 
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Two-Photon Excitation Fluorescence Microscopy of Redox Ratio 
Figure 2: MPM imaging of CRC cells with NADH and FAD autofluorescence and cell cytoplasm 
segmentation. 
 
 
 
Figure 2:A: NADH autofluorescence 
intensity image. 
Figure 2:B: NADH cell cytoplasm 
segmentation mask overlaid onto 
NADH image. 
 
Figure 2:B: FAD autofluorescence 
intensity image. 
Figure 2:C: NADH cell cytoplasm 
segmentation mask overlaid onto FAD 
image. 
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Figure 3: CRC cells experience slight changes in redox ratio distribution over the course of 5-
FU treatment. 
 
 
Figure 3: Histograms of redox ratio versus fraction of cells for 0-hour (214 cells), 16-hour (309 
cells), and 24-hour (324 cells) 10 µM 5-FU treatments. The frequency distribution is graphed as 
relative frequency (fraction of cells) versus redox ratio. Redox ratio bin number was determined 
using 𝐵𝑖𝑛 𝑁𝑢𝑚𝑏𝑒𝑟 = 𝐿𝑜𝑔2(𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑅𝑒𝑑𝑜𝑥 𝑅𝑎𝑡𝑖𝑜 𝑉𝑎𝑙𝑢𝑒𝑠 𝑓𝑜𝑟 𝐺𝑖𝑣𝑒𝑛 𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡). Redox 
ratio means and standard deviations are as follows: 0-hour treatment: µ=0.467, σ=0.0321; 16-hour 
treatment: µ=0.488, σ=0.0319; 24-hour treatment: µ=0.471, σ=0.0173. 
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Figure 4: Redox ratio increase to a maximum and then decreases over the course of 5-FU 
treatment. 
 
Figure 4: Mean and standard deviation of redox ratio values plotted versus 10 µM 5-FU 
exposure time. A nonparametric ANOVA (Kruskal-Wallis and post hoc Dunn’s Multiple 
Comparisons Tests) shows *p-value<0.0001 compared to the 0-hour treatment and #p-
value<0.0001 compared to the 16-hour treatment. This test was used because the data is not 
normally distributed and means of all groups are compared to each other with a Tukey 
multiplicity-adjusted alpha=0.05. 
Discussion 
Despite extensive optimization and iteration of the CC3 Western blot, the sensitivity of this 
blot protocol proved too low to accurately quantify CC3 expression through 5-FU exposure time. 
Intense protein ladder and β-actin control bands suggest SDS-PAGE and transfer were effective. 
Possible errors preventing intense CC3 bands include high resistance of the HCT116 CRC cell line 
to 5-FU treatment; however, at 5-FU concentrations of 10 and 20 µM apoptosis should occur. (7, 
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22) The cell population may have simply been to small to produce adequate amounts of CC3 for 
detection via Western blot, or, similarly, the CC3 protein fraction may have been a very small 
fraction of the total protein quantified via BCA assay, affecting Western blot sample preparation. 
Also, the timepoints selected may not have corresponded well with the apoptosis window in culture 
and expressed CC3 broke down before lysate collection. (2, 3, 23) Lastly, it is possible the primary 
and secondary CC3 antibodies used here were simply not specific enough for the amounts of CC3 
present. Apoptosis in culture is readily visible with a brightfield microscope; lack of visible 
apoptotic debris in culture in these experiments suggests the cells were highly resistant to 
treatment, or the exposure times did not match the apoptosis window well. (2) 
Redox ratio values exhibited a significant increase with 5-FU exposure time, followed by 
a significant decrease back to values not significantly different from the control group. This trend 
may be explained by MPM images capturing basal CRC redox ratio values at 0 hours of 5-FU 
exposure; then, after some period of 5-FU exposure, MPM images capture cells undergoing 
apoptosis and experiencing higher levels of oxidative stress resulting from an increase in reactive 
oxygen species associated with the apoptosis cascade. (2) After 24 hours of 5-FU exposure, cells 
with low resistance to 5-FU have undergone apoptosis, leaving high resistance cells with 
essentially basal CRC oxidative stress and redox ratio. Higher levels of reactive oxygen species 
would result in an oxidized mitochondrial state, oxidized flavoproteins such as FAD, and an 
increase in redox ratio. (17) 
However, some discrepancies should be noted in the redox ratio imaging methods and 
results. First, several limitations of redox ratio as an indicator of metabolic activity are ignored in 
these experiments. Namely, other cellular chromophores with similar excitation and emission 
spectra to NADH and FAD, such as keratin, lipofuscin, and retinol, may have contributed signal 
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to NADH and FAD measurements. (21) Secondly, the redox ratio results presented here may be 
interpreted differently considering a unique cancer metabolic profile—the Warburg Effect. The 
Warburg Effect describes a reprogramming of cellular metabolism that allows cells to 
preferentially metabolize glucose, resorting to glycolysis rather than oxidative phosphorylation. 
This has been explained as a mechanism for rapid ATP generation to support uncontrolled cancer 
cell proliferation. (14, 24) If the HCT116 CRC cells produce energy mainly by the glycolytic 
pathway and NADH is considered as the primary metabolic cofactor involved in glycolysis and 
FAD is considered as essentially isolated to oxidative phosphorylation, then increases in the redox 
ratio here would indicate an increase in metabolic activity with 5-FU treatment—the opposite of 
the expected effect. Some research suggests CRC cells employ this glycolytic ATP production. 
(25, 26) However, even the binary interpretation of redox ratio as either an indicator of oxidative 
phosphorylation or glycolysis for energy production condones other potential processes such as 
glutominolysis and fatty acid biosynthesis that may offer further explanation into the actual effects 
of 5-FU on CRC redox ratio and apoptosis. (21) It remains that a preponderance of evidence shows 
decreases in redox ratio with chemotherapy, contrary to the result presented here. Increases in 
redox ratio were, however, associated with changes to a metastatic phenotype in past studies. (14-
20)  
Conclusion and Future Directions 
Because of complex tumor biology and interpatient heterogeneity, a need remains to monitor 
tumor response to therapy at an individual level through real time, sensitive methods in order to 
minimize negative side effects, expenses, and lack of health benefits associated with ineffective 
treatments. Then, health workers can identify and proceed with higher-efficacy treatments more 
efficiently. TPEFM technology provides many advantages over traditional methods for 
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quantifying tumor response to therapy and may help realize individual cancer care with optical, 
metabolic imaging of redox ratio. In CRC cells, however, a benchmark of 5-FU induced apoptosis 
rates should be constructed to corroborate trends in redox ratio. Future experiments should 
investigate using other apoptosis assays, such as an Annexin V apoptosis assay, or even a 
combination of assays. (2, 3) Then, a reputable standard of apoptosis in this context of cell line 
and chemotherapy can be used to evaluate MPM methods. Secondly, redox ratio should be 
investigated with other assays that shed light on the metabolic profile of the cells so that more 
concrete results can be reached in terms of the significance of changes in this redox ratio and how 
those changes might relate to 5-FU induced apoptosis. Combinations of multiple markers to 
monitor tumor response to treatment, including redox ratio and additional 
molecular/morphological responses, should be investigated as well. (2, 3) A move toward more 
physiologically relevant modelling with a 3-D tumor spheroid to better predict results of future in 
vivo experiments may also prove beneficial. (27) Lastly, the objectives presented here may be 
extended to other cancer types, quantification of response to novel drugs, and monitoring of 
dysplastic and metastatic progression. 
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